Published • loading... • Updated
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Two insiders sold shares after RSU vesting as MannKind said royalties from United Therapeutics remain uncertain in its latest filing.
Summary by The Motley Fool
1 Articles
1 Articles
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Key PointsThe transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share.The disposition represented 9% of direct common stock holdings, which included shares delivered upon the recent vesting of performance-based awards.The activity consisted of 24,395 shares withheld for tax obligations and 52,485 shares sold under a Rule 10b5-1 trading plan established on December 2…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
